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Abstract
Background: Hepatitis E virus (HEV) has been described as an emerging pathogen in Brazil and seems to be widely
disseminated among swine herds. An autochthonous human case of acute hepatitis E was recently reported. To
obtain a better understanding of the phenotypic profiles of both human and swine HEV strains, a experimental
study was conducted using the animal model, Macaca fascicularis.
Methods: Six cynomolgus monkeys (Macaca fascicularis) were inoculated intravenously with swine HEV genotype 3
that was isolated from naturally and experimentally infected pigs in Brazil and the Netherlands. Two other monkeys
were inoculated with HEV genotype 3 that was recovered from Brazilian and Argentinean patients with locally
acquired acute and fulminant hepatitis E. The haematological, biochemical, and virological parameters of all animals
were monitored for 67 days.
Results: Subclinical hepatitis was observed in all monkeys after inoculation with HEV genotype 3 that was
recovered from the infected swine and human patients. HEV RNA was detected in the serum and/or faeces of 6 out
of the 8 cynomolgus monkeys between 5 and 53 days after inoculation. The mild inflammation of liver tissues and
elevations of discrete liver enzymes were observed. Seroconversions to anti-HEV IgM and/or IgG were detected in 7
animals. Reactivities to anti-HEV IgA were also detected in the salivary samples of 3 animals. Interestingly, all of the
infected monkeys showed severe lymphopenia and a trend toward monocytosis, which coincided with elevations
in alanine aminotransferase and antibody titres.
Conclusions: The ability of HEV to cross the species barrier was confirmed for both the swine (Brazilian and Dutch)
and human (Argentinean) strains, thus reinforcing the zoonotic risk of hepatitis E in South America. Cynomolgus
monkeys that were infected with HEV genotype 3 developed subclinical hepatitis that was associated with
haematological changes. Haematological approaches should be considered in future studies of HEV infection.
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Background
Infection with hepatitis E virus (HEV) has been well
documented in endemic areas, such as southeastern and
central Asia, the Middle East, the northern and western
parts of Africa, and North America [1]. In areas of poor
sanitation, epidemics occur periodically, and infection is
mainly transmitted via the faecal contamination of water.
However, the global burden of HEV infection is more
influenced by sporadically transmitted hepatitis cases
than by epidemics [2]. In South America and other non-
endemic areas, epidemics of hepatitis E have not yet been
reported. Nevertheless, sporadic cases of both acute, self-
limited hepatitis and fulminant hepatic failure have been
reported in Venezuela, Brazil, and Argentina [3]. In most
of these cases, the human isolates were related to swine
genotype 3 HEV strains from the same region.
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In Brazil, HEV genotype 3 seems to be widely dissemi-
nated. The virus has been detected in swine and effluent
samples from farms and slaughterhouses. Among swine
handlers, the anti-HEV IgG seroprevalence is estimated
to be 6 to 8% [4,5] and is approximately 2% in urban
areas [6,7]. Although national data show high numbers
of alleged cases, the true incidence of hepatitis E in
the Brazilian population is uncertain because a testing
protocol for HEV has not yet been established. A retro-
spective study of sera from patients with non-A-C acute
hepatitis from 2005–2009 led to the identification of the
first autochthonous human case of acute HEV infection.
The genetic relatedness of this strain and the genotype 3
HEV in pigs is indicative of the zoonotic circulation of
HEV in Brazil [8-10].
Infection studies using Macaca fascicularis, Aotus
trivirgatus, Macaca mulatta, and Pan troglodytes that
have evaluated the course of HEV infection have been pre-
viously described [11-16]. These studies have created an
experimental foundation for the understanding of the
immunological behaviour of HEV, including the cross-
reactivities among different isolated strains [17,18] and the
conferral of cross-immunity among genotypes 3 and 4 in
swine hosts [19]. HEV genotype 3 shows dose-dependent
infectivity [20] and is able to cross species barriers [21-23],
causing infection in species such as the cynomolgus mon-
key [24], which is considered to be a well-established
model for human HEV infection.
Currently, most experimental studies of HEV investi-
gate only virological and hepatic parameters. However,
there is limited information available describing the
extra-hepatic manifestations of HEV infection, including
a few reports highlighting other clinical findings, such as
pancreatitis, thrombocytopenia, aplastic anaemia, acute
thyroiditis, glomerulonephritis, and neurologic disorders,
as reviewed by Dalton et al. [25]. To obtain a better un-
derstanding of the phenotypic profiles of both human
and swine Brazilian HEV strains, a descriptive study was
conducted in the experimental model Macaca fascicularis.
Human and swine HEV samples from Argentina and
the Netherlands were also used as inocula. This article
describes, for the first time, haematological disorders that




Ten clinically healthy young adult cynomolgus monkeys,
each weighing 1.5–6.0 kg, were provided for use in
this study by the Non-Human Primates Breeding Ser-
vice Centre (CECAL) of the Oswaldo Cruz Foundation
(Fiocruz), Rio de Janeiro, Brazil. The study protocol was
approved (L-0033/07) by the Ethics Committee for Ani-
mal Use (CEUA), Fiocruz, and was conducted in strict
accordance with the recommendations from the Guide for
the Care and Use of Laboratory Animals of the Brazilian
Society of Science in Laboratory Animals (SBCAL) and
the National Council for Control of Animal Experimen-
tation (CONCEA, Brazil). The animals that were se-
lected for the study were free of simian immunodeficiency
virus (SIV) and simian type D retrovirus (SRV/D). They
were also negative for anti-HEV IgG in their sera and
had no inflammatory changes in their pre-study liver bi-
opsies. During the study and quarantine periods, the
monkeys were maintained at Animal Biosafety Level 2
in CECAL, Fiocruz, and were kept individually in stain-
less steel squeeze-back cages in a climate-controlled room
(temperature of 22 ± 1°C and humidity 55 ± 5%) with a
12 h light/dark cycle.
Inocula
The Brazilian swine HEV (Br-swine) genotype 3b
(GenBank EF591853.1) strain was isolated from a faecal
suspension that was obtained from a naturally infected
pig from a commercial farm in Rio de Janeiro state [12].
The Dutch swine HEV (D-swine) genotype 3 (GenBank
DQ996399) strain, which was kindly supplied by the Cen-
tral Veterinary Institute of Wageningen University and
Research Centre, the Netherlands, was obtained from an
experimentally infected pig [23].
The Brazilian human HEV (Br-human) genotype 3b
(GenBank GQ421465) strain was isolated from a 1-ml
serum sample that was obtained from a 30-year-old male
with acute hepatitis E [26]. The Argentinean human HEV
(Ar-human) sample was kindly provided by the Dr. Carlos
Malbran Institute, Buenos Aires, and was prepared from a
pool of 1 ml of serum and the faeces of a 3-month-old fe-
male with fulminant acute hepatic failure (Table 1). This
study was approved by the institutional review boards
(CEP-Fiocruz No. 22/03), and a signed informed consent
form was obtained from each participant.
Experimental design
Eight cynomolgus monkeys were intravenously inoculated
with either Br-swine (monkeys X15, Q11, and I3), Dutch
swine (O1, G3, and F3), Br-human (J3), or Ar-human (R7)
viruses. As a control, 2 monkeys (Q12 and I2) were in-
oculated with a 10% phosphate-buffered saline (PBS) so-
lution (pH 7.3). All of the animals had been previously
screened for the anti-hepatitis A virus (HAV) and anti-
HEV antibodies by the enzyme-linked immunosorbent
assay (ELISA) using the Bioelisa HAV kit (Spain Biokit,
Barcelona, Spain) and the IgG anti-HEV kit (MP Biomedi-
cals, California, USA), respectively. During the study and
quarantine periods, the monkeys were housed in an Ani-
mal Biosafety Level 2 facility. The animals were clinically
monitored for 67 days post infection (dpi); they were moni-
tored daily by the veterinary staff and checked weekly for
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rectal temperature and weight changes. Whole-blood sam-
ples (3 ml) were collected by venipuncture at 0, 7, 14, 25,
32, 39, 46, 53, and 67 dpi for HEV RNA and antibody de-
tection. Faecal samples were collected at 0, 5, 7, 12, 14, 18,
21, 25, 27, 32, 35, 39, 42, 49, 53, 56, 63, and 67 dpi for HEV
RNA detection and were stored in polystyrene tubes
at −20°C until use. Salivary samples were collected from
Q11, J3, O1, G3, F3, I3, and Q12 using OraSure® collection
devices (OraSure Technologies Incorporated, Pennsylvania,
USA) at 0, 7, 14, 21, 28, 35, 42, and 53 dpi for IgA detec-
tion. For the collection of saliva and blood and liver
biopsies (weekly), the animals were anaesthetised with
ketamine hydrochloride at 20 mg/kg (Vetanarcol, König,
Argentina) and xylazine hydrochloride at 0.1 mg/kg
(Syntec Brazil, São Paulo, Brazil). At 67 dpi, all of the ani-
mals were euthanised under deep barbiturate anaesthesia
with sodium thiopental 2.5% at 25 mg/kg (Thiopentax,
Cristalia, São Paulo, Brazil), which was delivered intraven-
ously. Subsequently, cardiac punctures were performed,
and the animals were euthanised by exsanguination.
ELISA tests
The presence of anti-HEV IgG was detected using a
commercial ELISA Kit (MP Biomedicals, Ohio, USA)
according to the manufacturer’s instructions. Pre- and
post-inoculation samples were also tested for macaque
anti-HEV IgG, IgM (sera), and IgA (saliva) using a modi-
fied protocol (Dr. Julio Moran Laboratories, Zurich,
Switzerland) for the commercially available DiaCheck anti-
human HEV antibody assay with an adapted goat anti-
macaque immunoglobulin conjugate (Fitzgerald Industries
International, Inc., Massachusetts, USA).
Real-time PCR (qPCR)
Total RNA was extracted from 140 μl of a serum and
faecal suspension (10% w/v in PBS) using the QIAamp
Viral RNA Kit (Qiagen, California, USA). Reverse tran-
scription was performed using 25 μl of RNA, 200 IU/ml
Superscript III reverse transcriptase (Life technologies
Corp., USA), and 20 pmol/μl random primer (Life tech-
nologies Corp., USA). A quantitative TaqMan real-time
PCR assay was performed using a standard curve that
was generated with a plasmid clone from a Brazilian
swine strain that had been previously characterised as
having genotype 3 [26]. Plasmid serial dilutions ran-
ging from 108 to 101 were used to provide quantification
parameters.
The qPCR reactions were performed in duplicate in a
final volume of 25 μl consisting of 12.5 μl Universal PCR
Master Mix (Life technologies Corp., USA), 5 μl cDNA,
endonuclease-free water, and the previously described
primers and probes [27]. The following conditions were
used for the qPCR: 50°C for 2 min to activate the uracil
N-glycosylase (UNG), an initial denaturation step at 95°C
for 15 min, 45 cycles of denaturation at 95°C for 10 sec,
and annealing/extension at 55°C for 1 min. The ampli-
fication data were collected and analysed with Applied
Biosystems 7500 Software® v2.0. Samples were considered
to be positive when the signal crossed the threshold line,
presenting a characteristic sigmoid curve. The number of
viral genome copies (GC) was determined by adjusting
the values according to the volumes that were used for
each step of the procedure (i.e., extraction, cDNA synthe-
sis, and the qPCR reaction).
Liver function
Alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), gamma-glutamyl transferase (GGT), and
total bilirubin (Tb) serum levels were determined using
a commercial enzymatic colorimetric method (Abbott,
IL, USA). The baseline levels were obtained from blood
samples of the pre-inoculation and control groups.
Table 1 Sources of hepatitis E virus inocula used to infect the cynomolgus monkeys
Source Inocula Anti-HEV
serology
HEV RT-PCR/real-time PCR Genotype Age of monkey
(years)
Animal ID
Swine Pooled faeces (3.0 ml) _ HEV RNA+/105 copies/ml 3 15 I3
18 Q11
2 X15
Swine Pooled faeces (3.0 ml) _ HEV RNA+/106 copies/ml 3 11 O1
17 G3
19 F3
Child, female, 3 months old
(FALF*)
Serum and faeces (1.0 ml) Undetectable Undetectable/103 copies/ml 3 7 R7
Adult, male, 30 years old
(AH**)
Serum (1.0 ml) IgG+/IgM+ HEV RNA+/106 copies/ml 3 14 J3
- 10% Phosphate-buffered
saline (1.0 ml)
_ Undetectable _ 16 I2
18 Q12
FALF* – fatal acute liver failure; AH** – acute hepatitis.
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Peripheral blood cell counts
Haematological, biochemical, and serological parame-
ters were established for each animal using individual
pre-inoculation samples. Blood samples were collected
using ethylenediaminetetraacetic acid (EDTA) capillary
tubes. Peripheral blood cells were counted using a commer-
cial veterinary haematology analyser (Roche Diagnostica,
Brazil).
Histopathological analyses
Liver biopsies were collected at 0, 7, 14, 25, 32, 39, 46,
53, and 67 dpi by ultrasound-guided liver puncture, as
described previously [28]. A portion of each sample was
stored in 10% buffered formalin (pH 7.0) before being
processed and embedded in paraffin according to stand-
ard methods. Paraffin blocks were sectioned at 4 μm and
stained with haematoxylin-eosin, Giemsa stain, and
Masson’s trichrome stain (Sigma-Aldrich, USA). The slides
were examined under light microscopy, and inflammatory
lesions were quantified using a scale from 0 to 4 that was
based on the number of focal mononuclear cell infiltrates
per 10 hepatic lobules: 0 = no inflammation, 1 = 1 to 2 focal
infiltrates (poor), 2 = 3 to 5 focal infiltrates (mild), 3 = 6
to 10 focal infiltrates (moderate), and 4 = over 10 focal
infiltrates (severe) as described previously [29]. A portion
of each liver sample was stored in liquid nitrogen until
the HEV analysis was performed. Pre-inoculation liver
biopsies were performed to confirm the absence of other
liver diseases.
HEV antigen detection
Frozen liver sections (4 μm) that had been obtained at
67 dpi were examined by indirect immunofluorescence
using a rabbit anti-HEV polyclonal antibody at a 1:150 di-
lution (Research Diagnostics Inc., USA) as the primary
antibody (1 mg/ml), followed by a FITC-labelled goat anti-
rabbit IgG antibody (2 mg/ml) at a 1:750 dilution (Sigma-
Aldrich) as the secondary antibody. The slides were
counterstained with Evans Blue, mounted with ProLong©
Gold Slow Fade in glycerol with DAPI stain (Life technolo-
gies Corp., USA), and covered with a coverslip. Images of
the positive fields were obtained by confocal microscopy
(LSM Zeiss 510 Meta Carl Zeiss, Oberkochen, Germany).
Statistical analyses
Data are expressed as the means ± standard deviations
(SD). Statistical analyses for the continuous variables
were performed using 2-way ANOVA non-parametric
statistics. A value of P < 0.05 was considered to be statis-
tically significant. All of the calculations were performed
using The R Project for Statistical Computing [30], and
the graphics were produced using GraphPad InStat ver-
sion 5.01 for Windows (GraphPad Software, San Diego,
CA, USA).
Results
Cynomolgus monkeys inoculated with faecal suspensions
from Brazilian and Dutch swine
Detection of HEV RNA in serum and faecal samples
After inoculation with the Brazilian swine HEV (Br-swine),
all of the animals were successfully infected. HEV RNA
was detected by qPCR in the sera and faeces of all infected
cynomolgus monkeys with the exception of monkey X15,
which did not have viraemia but exhibited viral shedding
in the faeces between 14 and 21 dpi. One animal showed a
protracted pattern of viral shedding in the faeces from 21
dpi onwards. Out of the 3 animals that were inoculated
with the Dutch swine HEV (D-swine), HEV RNA was
detected at earlier time points in 2 (O1 and G3), with the
virus being detected in the faeces at 5 or 7 dpi and in the
sera at 7 to 14 dpi (Table 2).
Biochemical and histopathological findings
Individual values for ALT, AST, GGT, and Tb did not vary
significantly during the follow-up period. Exceptions in-
cluded monkeys X15 (inoculated with the Br-swine virus)
and F3 (inoculated with D-swine), of which serum levels
for ALT, AST, and GGT were higher compared with their
respective pre-inoculation values and the cynomolgus
standard normal values (Table 2).
The histological analyses of the pre-inoculation liver
sections were normal in all animals. After inoculation,
the most prominent inflammatory reaction was observed
for monkey X15 (Brazilian inoculum), which exhibited a
mild portal inflammation with lymphocytes and histio-
cytes. Monkeys I3 and Q11 showed mild to moderate
hyperplasia of the Ito cells from day 0 throughout the
follow-up period. Cynomolgus monkeys that were inocu-
lated with the Dutch swine HEV showed changes that were
compatible with biochemical and histological HEV-related
hepatitis, including mild inflammatory reactions with
multifocal lobular lymphohistiocytic infiltrates (Figure 1B
and Table 2). Slight to mild fatty changes and mild diffuse
swelling of the hepatic cells were detected in all of the ani-
mals, even in the absence of an inflammatory response.
Monkeys I3 and Q11 showed mild to moderate Ito cell
hyperplasia from day 0 until the end of the experiment
(Figure 1A and Table 2).
Detection of HEV antibodies in serum and saliva
Animals that were inoculated with the Br-swine inocu-
lum (Figure 2C) exhibited specific antibody responses,
with their IgG and IgM serum titres beginning to rise at
25 dpi. The exception was monkey I3, for which the only
detectable antibody was salivary IgA.
All animals that were inoculated with the D-swine
HEV showed IgM, IgG, and IgA anti-HEV titres in the
serum samples that were collected during the follow-up
period. Both IgA and IgM were transient and decreased
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after 46 and 55 dpi, respectively (Figure 1B). The IgG
titre remained high until the end of the study. The
highest salivary IgA titre was detected at 39 dpi. In mon-
key F3, the highest IgA (serum and saliva), IgM, and IgG
titres were detected immediately following HEV inocu-
lation. Focal necrosis (Figure 2A) and HEV Ag were de-
tectable until 67 dpi (Figure 2B). Monkeys O1 and G3
seroconverted and had biochemical and histological hepa-
titis in association with transient viraemia and faecal shed-
ding. In monkey F3, sudden rises in serum IgM, IgG, and
IgA titres occurred at 7 dpi, suggesting a pre-exposure
to HEV without detectable HEV antibodies in the pre-
inoculation screening (Figure 1B).
Cynomolgus monkeys inoculated with biological samples
from patients from Brazil and Argentina
Cynomolgus monkey inoculated with Brazilian human HEV
The animal that was inoculated with the Brazilian human
virus (cynomolgus J3) exhibited rising levels of anti-HEV
IgG antibodies in association with the development of
inflammatory liver lesions, which was consistent with
immunomediated liver injury (Table 2). Slight to mild fatty
changes and mild diffuse swelling of the hepatic cells were
found in the pre-inoculation liver sample in addition to
those that were sampled throughout the experiment. At 46
and 53 dpi, this monkey showed mild portal infiltration,
and at necropsy, the liver histopathology was scored as 1
using the severity assessment scoring system for inflamma-
tory lesions (Table 2). Two slight variations in ALT levels
were observed at 25 and 39 dpi. A change in GGT was
detected at 25 dpi, and variations in TB were detected at 7,
14, and 32 dpi (Figure 1D).
Cynomolgus monkey inoculated with Argentinean human HEV
Cynomolgus monkey R7 was inoculated with the
Argentinean human HEV sample (Ar-human) and devel-
oped biochemical and histological hepatitis with viral shed-
ding. Mild to moderate hyperplasia of the Ito cells and
mild portal infiltration were observed at 25 dpi and 7 dpi,
respectively. Liver samples that were obtained at necropsy
showed histological recovery (Table 2 and Figure 1C).
Negative controls
Both of the negative controls (monkeys Q12 and I2) de-
veloped non-significant biochemical alterations directly
following the liver puncture procedures. Liver biopsies




ALT AST GGT Tb **Liver
injury
HEV RNA detection ***anti-HEV Clinical interpretation****
(IU/dL) (#maximum
value obtained)
(Score) (dpi*) (EIA reactivity)
Serum Saliva
Serum Faeces IgM IgG IgA IgA
Br-swine X15 73 295 315 0.8 2 — 14 - 21 + + + nt Subclinical hepatitis E
Q11 24 31 64 0.7 1 14 7 - 21 + + + - Subclinical hepatitis E without
biochemical disorders
I3 40 54 224 0.8 2 39 - 53 21 - 53 - - - + Subclinical hepatitis E
D-swine 01 40 119 237 0.8 1 14 5 - 18 + + + - Subclinical hepatitis E
G3 32 42 138 0.8 1 7 - 14 7 - 18 + + + +/− Subclinical hepatitis E without
biochemical disorders
F3 99 302 238 0.7 1 — — + + + + Biochemical and histological
hepatitis E
Br-human J3 57/46 50 293 0.8 1 — — - + - - Biochemical and histological
hepatitis E
Ar-human R7 21 213 188 0.8 0 — 14 - 27 + + + nt Subclinical hepatitis E
Control I2 21 43 92 0.8 0 — — - - - nt Uninfected
Q12 21 116 103 0.7 0 — — - - - - Uninfected
*dpi: days post inoculation.
**Liver sections were prepared from large liver samples collected during necropsy; liver injury score (adapted from [29]): 0 – without inflammation, 1 – 1 to 2
lymphohistiocytic inflammatory infiltrates/10 liver lobules, 2–3 to 5 inflammatory infiltrates/10 lobules, 3–6 to 10 inflammatory infiltrates/10 lobules, 4- >10
inflammatory infiltrates/10 lobules (adapted from [29]).
***DiaCheck anti-human HEV antibody assay that was modified with a goat anti-macaque secondary antibody.
#The maximum value obtained during the entire follow-up period is provided.
****Subclinical hepatitis was considered when the animals presented only laboratorial finds of infection, Biochemical hepatitis was considered using species-specific normal
values and pre-inoculation values. Liver enzymes values were elevated at least twice above baseline in the context of an HEV infection. Histological hepatitis was
considered when the animals presented lymphohistiocytic inflammatory infiltrates in liver biopsy.
Br: Brazilian, Ar: Argentinian, D: Dutch, EIA: Enzyme immunoassay, nt: not tested, (they did not produced enough saliva).
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Figure 1 Virological, inflammatory, biochemical, and antibody titre assessments from selected cynomolgus inoculated with HEV
genotype 3. The data for monkeys Q11, F3, R7, J3, and Q12 are represented in panels A, B, C, D, and E, respectively. The values of antibody
levels are reported as optical density/cutoff ratios, with a OD/CO > 1.0 considered positive in the DiaCheck anti-human HEV antibody assay that
was modified for use with goat anti-macaque secondary antibodies. Underlined values are considered changed compared with baseline levels.
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were scored as 0 using the severity assessment scoring
system for inflammatory lesions (Figure 1E).
Peripheral blood cell counts
In general, the average number of platelets and red
blood cells did not change over the course of the experi-
ment. However, severe episodes of lymphopenia (< 200
cells/mm3) were observed throughout the follow-up period.
The average lymphocyte count was reduced (P < 0.01) in
comparison with the baseline value of lymphocytes in
the peripheral blood (2,800 ± 1,000 cells/ml) (Figures 3A
and 3B). Discrete monocytosis (> 900 cells/mm3) was also
observed in the inoculated animals (Figures 3C and 3D).
Discussion
This article describes a successful, original approach for
the experimental infection of cynomolgus macaques with
HEV genotype 3 from different sources (human and swine)
and different clinical manifestations. In their original hosts,
these viruses were associated with varying clinical manifes-
tations, ranging from none in the swine to fatal acute liver
failure or acute hepatitis in the humans. HEV samples from
different geographical regions, including Argentina, The
Netherland and Brazil where hepatitis E is rare and/or
under-diagnosed, were used in the present study. The
intravenous route was employed for inoculation to ensure
the best bioavailability of the inocula. Furthermore, our
previous experience with the experimental transmission of
enterically transmitted viral hepatitis in different non-
human primates indicated that the only difference between
oral and intravenous inoculation is the period of viral incu-
bation, which is generally shorter for the intravenous route.
Similar to the other experimental studies employing the
cynomolgus monkey as a model for HEV infection, we
found slight biochemical and histological alterations [31].
We observed that the first HEV-related event was viral
shedding (at 5 to 21 dpi), as has been previously reported
[32]. We assume that all of the animals presented with sub-
clinical viral hepatitis independent of the source of the in-
oculum (swine or human) and the clinical presentation of
the original host organism [22,31]. Even the animal that
was inoculated with the Brazilian human HEV strain
showed rising titres of anti-HEV IgG after 39 dpi. In-
deed, there were no indications that the passive transfer of
antibodies had occurred (Figure 1D). A late seroconversion
Figure 2 Liver sections from cynomolgus (A and B) and Brazilian
HEV infected pig (C). A. Focal area of hepatocyte necrosis with
polymorphic inflammation (histiocytes, lymphocytes, and neutrophils).
Stained with hematoxylin and eosin; B. Detection of HEV antigen
(marked in green) in the cytoplasm of hepatocytes and Kupffer cells at
67 dpi (cynomolgus G3); and C. Detection of HEV antigen (marked
in red) in the cytoplasm of hepatocytes from a naturally infected pig
obtained from a commercial pig farm in Brazil (inoculum).
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to HEV (at 6–7 weeks pi) has previously been detected in
cynomolgus monkeys that were inoculated intravenously
with HEV from rabbits [33]. The absence of detectable
HEV RNA in the faeces or sera may be explained by the
presence of an IgG antibody response in the inoculum
(human serum), which may have reduced the infectivity
of the HEV particles, and/or by the lengthy time period
that the samples had been stored. However, in both of
these scenarios, the HEV peptides would have sensitised
the macaque immune systems.
Cynomolgus monkey F3 presented with biochemical
and histological hepatitis E (Table 2) without detectable
viraemia or faecal shedding. However, early increases in
antibody titres (IgM, IgA, and IgG) were observed con-
comitantly with slow and progressive ALT elevation. Ap-
parently, the HEV infection was controlled in this
monkey, accounting for the small number of focal in-
flammatory areas. A previous natural infection [34,35] or
another HEV-like pathogen may explain this resistance
to infection [36,37]. This result was intriguing because
the main criterion for the inclusion of cynomolgus mon-
keys in our experimental protocol was the absence of
anti-HEV IgG in the pre-inoculation serum. All of the
animals that were provided by the animal breeding centre
had been screened twice for HEV antibodies using two
different assays. Sixteen out of the 76 captive cynomolgus
monkeys were reactive to anti-HEV IgG in this screening
and were therefore excluded from this study. All of the
non-reactive animals were considered to be naive to HEV
infection. Other authors have assumed that HEV or
an HEV-related agent circulates naturally among In-
dian macaques [34,35,38,39]. A previous natural exposure
may prevent a new (experimental) HEV infection [40,41].
In contrast, cynomolgus monkey I3 (Table 2) showed
lymphopenia, prolonged viraemia (starting at 39 dpi), and
faecal shedding (starting at 19 dpi) without seroconversion
until the end of the experiment and possibly beyond that
period. Such a pattern of prolonged viraemia and viral
elimination without seroconversion or liver enzyme eleva-
tion has been described for HEV-infected, immunocom-
promised individuals [42-44], haemodialysis patients [45],
and an immature neonate [44]. The protective roles of spe-
cific antibodies in controlling HEV infection have been
confirmed in non-human primate studies [40,46-48] for
both naturally acquired and experimentally induced infec-
tions [38,48,49] and in convalescent human patients [50].
The presence of activated lymphocytes during the reso-
lution of hepatitis E infection has been demonstrated in
acute hepatitis [51], acute liver failure [52], and acute hepa-
titis during pregnancy [53].
Interestingly, all of the infected monkeys showed se-
vere lymphopenia and discrete monocytosis, coinciding
with elevations in ALT and antibody titres. This study




















































































































Figure 3 Haematological changes in cynomolgus monkeys experimentally infected with HEV. Lymphopenia was observed in the HEV-inoculated
groups. An average lymphocyte was calculated at each of nine time points for all monkeys in each group (A) and in individuals (B). A trend toward
monocytosis was observed in the inoculated groups. An average monocyte count for all HEV-inoculated monkeys in each group (C), and significant
differences were observed in some individuals (D) (ANOVA, **P < 0.01, *P < 0.05).
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that are associated with HEV infection, thus providing
an additional parameter for future experimental proto-
cols. In addition, we observed a progressive reduction in
the average neutrophil counts of the inoculated animals
compared with their baseline levels (data not shown).
Other uncommon extra-hepatic manifestations, such as
thrombocytopenia, anaemia [54], and neurological symp-
toms, have been previously described in HEV-infected
patients [55]. Monocytosis has also been observed, typic-
ally in animals that have been inoculated with swine
HEV. However, the restricted number of animals and in-
ocula and the large individual variability among haem-
atological values do not allow for precise conclusions
to be drawn. The lymphohistiocytic hepatitis that was
detected in our study has also been described in a rodent
model of infection with HEV genotype 4 [56]. The ele-
vated presence of infiltrated lymphocytes in the portal
area and the focal inflammation that was detected in our
study may be consequences of the intra-hepatic flow of
lymphocytes, which was observed during this study for
CD8+ cells in the cynomolgus monkeys with subclinical
hepatitis E (data not shown). The same findings have
also been reported in transplant patients with chronic
hepatitis E [57] and in the liver parenchyma after HEV-
induced acute liver failure [56]. Other authors have also
observed lymphopenia in patients with hepatitis-virus-
associated aplastic anaemia (HAA), suggesting that HAA
may be influenced by the immune-mediated destruction
of bone marrow [58]. Several viruses are considered to
be triggers for autoimmunity and overt autoimmune dis-
ease. The virus-specific evasion mechanism, which is
termed molecular mimicry, may serve as an accelerating
factor for hepatic and extra-hepatic pathogenesis [59].
Further immunological approaches using peripheral
blood cells and their precursors in bone marrow samples
will contribute to understand the haematological mani-
festations of hepatitis E infection.
With the goal of improving HEV diagnoses, the serum
titres for the IgA and IgM immunoglobulins were mea-
sured and showed similar profiles, with temporary in-
creases being observed in most of the animals that were
considered to be HEV-infected. Although the collection
of salivary samples is less invasive than that of blood, the
irregularities and fluctuations in the specific IgA levels
in the saliva during the follow-up period indicate that
this marker cannot replace classical testing that uses
serum antibodies as markers for acute infection in rou-
tine diagnostics.
Our study indicate that HEV is capable of inter-species
infection, which has been corroborated by other studies
that have been conducted with HEV genotype 3 [21,60].
Because autochthonous hepatitis E cases have been associ-
ated with genotype 3 isolates, the zoonotic aspect of HEV
infection should be considered in non-endemic, developing
countries, such as Brazil and Argentina. Additional sero-
logical, molecular, and epidemiological studies will provide
a better understanding of the dynamics and profile of this
disease in Latin America.
Conclusions
Finally, this work confirmed the ability of HEV to cross the
species barrier for both the swine (Brazilian and Dutch)
and human (Argentinean) strains, thus reinforcing the zoo-
notic risk of hepatitis E in South America. Cynomolgus
monkeys that were infected with HEV genotype 3, obtained
from different clinical presentations, developed subclinical
hepatitis that was associated with haematological changes.
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